Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
Chad J. Swanson(Eisai (United States)), Jeffrey L. Cummings(University of California, Los Angeles), Scott Berry(Queen's University), Shobha Dhadda(Eisai (United States)), Robert J. Gordon(University of Windsor), Larisa Reyderman(Eisai (United States)), Donald A. Berry(Berry & Associates (United States)), June Kaplow(Eisai (United States)), Yong Zhang(Eisai (United States)), Jinping Wang(University of Jinan), Akihiko Koyama(Eisai (United States)), Martin Rabe(Eisai (United States)), Lynn D. Kramer(Eisai (United States)), Lars Lannfelt(BioArctic Neuroscience (Sweden)), Robert Lai(Eisai (United Kingdom)), Heather Bradley(Eisai (United States))
Cited by 19
Related Papers
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease
|Nature Genetics|2011|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k
Alzheimer's disease
|Nature Reviews Disease Primers|2015|1.8k
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k